Sepso: Malsamoj inter versioj

El Vikipedio, la libera enciklopedio
[nekontrolita versio][kontrolita revizio]
Enhavo forigita Enhavo aldonita
Neniu resumo de redakto
Neniu resumo de redakto
Linio 6: Linio 6:
La sindromo de sistemika inflamrespondo kondukas al ampleksa aktivigo de la vojoj de [[inflamo|inflamado]] kaj [[sangkoaguliĝo|koaguliĝo]]. Tiu situacio povas evolui al malfunkcio de la [[cirkula sistemo]] kaj, eĉ post la plej optimigita terapio, al [[sindromo de multobla organo-malfunkciado]] kaj finfine [[morto]].
La sindromo de sistemika inflamrespondo kondukas al ampleksa aktivigo de la vojoj de [[inflamo|inflamado]] kaj [[sangkoaguliĝo|koaguliĝo]]. Tiu situacio povas evolui al malfunkcio de la [[cirkula sistemo]] kaj, eĉ post la plej optimigita terapio, al [[sindromo de multobla organo-malfunkciado]] kaj finfine [[morto]].


==Vidu ankaŭ==
<!--
* [[Antisepso]]
Sepsis is more common and also more dangerous in elderly, immunocompromised, and critically ill patients. It occurs in 2% of all hospitalizations and accounts for as much as 25% of [[intensive care medicine|intensive care unit]] (ICU) bed utilization. It is a major cause of death in intensive care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to >60% for [[septic shock]]. In the [[United States]], sepsis is the leading cause of death in non-coronary ICU patients, and the tenth most common cause of death overall according to 2000 data from the [[Centers for Disease Control and Prevention]] (Martin, ''et al.'', 2003).

A problem in the adequate management of septic patients has been the delay in administering the right treatment after sepsis has been recognized. A large international collaboration was established to educate people about sepsis and to improve patient outcomes with sepsis, entitled the "Surviving Sepsis Campaign." The Campaign has published an evidence-based review of management strategies for severe sepsis (Dellinger, ''et al.'', 2004), with the aim to publish a complete set of guidelines within 3 years.

==Treatment==
The therapy of sepsis rests on [[antibiotic]]s, surgical drainage of infected fluid collections, fluid replacement and appropriate support for organ dysfunction. This may include [[dialysis|hemodialysis]] in [[kidney]] failure, [[mechanical ventilation]] in [[lung|pulmonary]] dysfunction, transfusion of [[blood plasma]], [[platelets]] and coagulation factors to stabilize blood [[coagulation]], and drug and fluid therapy for circulatory failure. Ensuring adequate nutrition, if necessary by [[parenteral nutrition]], is important during prolonged illness.

Most therapies aimed at the inflammatory process itself have failed to improve outcome. However, [[drotrecogin]] (activated [[protein C]], one of the [[coagulation factor]]s) has been shown to decrease mortality from about 31% to about 25% in severe sepsis (Bernard, ''et al.'', 2001). Low dose [[cortisol]] treatment has shown promise for [[septic shock]] patients with relative [[adrenal insufficiency]].

==Related conditions==
* [[infection]] is an inflammatory response to a [[microorganism]], or the invasion of normally sterile host tissues by the organism.
* [[bacteraemia]] is the presence of [[bacterium|bacteria]] in the [[blood]]. Bacteraemia can occur in sepsis and other serious diseases such as infective [[endocarditis]], but it may also be a harmless and transient condition.
* [[diffuse intravascular coagulation]] (DIC)
* [[multiple organ dysfunction syndrome]]
* [[meningitis]], infection of the mesh that supports the brain, can be a complication of sepsis
* [[endocarditis]], infection of the inner layer of the heart, can also be a complication

==References==
* {{Journal reference issue | Author=Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group | Title=Efficacy and safety of recombinant human activated protein C for severe sepsis | Journal=[[New England Journal of Medicine]] | Volume=344 | Issue=10 | Year=2001 | Pages=699-709}} PMID 11236773
* {{Journal reference issue | Author=Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM; Surviving Sepsis Campaign Management Guidelines Committee | Title=Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock | Journal=Critical Care Medicine | Volume=32 | Issue=3 | Year=2004 | Pages=858-73}} PMID 15090974
* {{Journal reference issue | Author=Martin GS, Mannino DM, Eaton S, Moss M | Title=The epidemiology of sepsis in the United States from 1979 through 2000 | Journal=[[New England Journal of Medicine]] | Volume=348 | Issue=16 | Year=2003 | Pages=1546-54}} PMID 12700374

==External links==
* [http://www.survivingsepsis.org Surviving Sepsis Campaign]
* [http://www.sepsisforum.org International Sepsis Forum]
* [http://www.advancesinsepsis.com ''Advances in Sepsis'' journal]
-->


== Eksteraj ligiloj ==
== Eksteraj ligiloj ==

Kiel registrite je 18:15, 25 maj. 2017

Sepso (en la Greka Σήψις, putriĝo) estas serioza medicina kondiĉo, kaŭzita de signifa infekto kiu kondukas al sistemika inflamrespondo. La plej seriozaj kazoj de sepso inkluzivas la disigitan sepson (sepson kun akuta organo-malfunkcio) kaj sepsan ŝokon (sepson kun refraktiva arteria hipotensio).

Septikemio estas sepso de la sangsistemo kaŭzita de bakteremio, t.e. la esto de bakterioj en la sangsistemo. La vorto septikemio foje uziĝas ankaŭ por la plej ĝenerala signifo de sepso.

Simptomoj

La sindromo de sistemika inflamrespondo kondukas al ampleksa aktivigo de la vojoj de inflamado kaj koaguliĝo. Tiu situacio povas evolui al malfunkcio de la cirkula sistemo kaj, eĉ post la plej optimigita terapio, al sindromo de multobla organo-malfunkciado kaj finfine morto.

Vidu ankaŭ

Eksteraj ligiloj